News

Not found. Sign Up to RSS.app to use this feed. – create a new RSS feed at RSS.app. – (dnarepLKbC2tvEvA) Read more…

Samuel “Bo” Bartholomew is CEO of EvidenceCare and Managing Partner of Rockmont Investments. Bo leads EvidenceCare’s effort to empower better care decisions within the EHR so that every clinical decision will provide the right care at the right time. He also serves on the board of ProviderTrust and Mindera Health with the goal of bringing

Mindera Health is proud to introduce its Mind.Px™ test. Mind.Px is a simple test that uses a dermal biomarker patch to determine response to biologic drug class for psoriasis patients. Confidently prescribe the right biologic for your psoriasis patients! You submit the request. We do the rest. Connect with a representative to learn more, including

Tobin Dickerson joined MiNDERA from the The Scripps Research Institute where he was an Associate Professor in the Department of Chemistry and the Worm Institute for Research and Medicine from 2005-2019. He completed his BS with high honors in Chemistry from the University of Virginia in 1999, and subsequently was awarded his MA in Chemistry

Ted St. Martin, Chief Financial Officer, brings over 25 years of finance experience, including nearly 20 years in the life science industry at both commercial and clinical-stage companies. Prior to joining Mindera Health, Ted served as Vice President, Finance at Ventyx Biosciences, Inc., where he led all corporate finance and planning activities and played a

Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis,

Mr. Linh H. Le brings more than two decades of work experiences in the healthcare space, stemming from several industry sectors including molecular diagnostics, infectious diseases, and medical devices. He comes to Mindera from Predicine, where he served as Chief Financial Officer, leading key financial and infrastructure changes that enabled scalability and operational excellence across